![](/images/graphics-bg.png)
Vimentin 3, the New Hope, Differentiating RCC versus Oncocytoma
Joint Authors
Büttner, Reinhard
von Brandenstein, Melanie
Puetz, Katharina
Schlosser, Monika
Löser, Heike
Kallinowski, Joachim P.
Gödde, Daniel
Störkel, Stefan
Fries, Jochen W. U.
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-04-07
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Vimentin is currently used to differentiate between malignant renal carcinomas and benign oncocytomas.
Recent reports showing Vimentin positive oncocytomas seriously question the validity of this present diagnostic approach.
Vimentin 3 is a spliced variant and ends with a unique C-terminal ending after exon 7 which differentiates it from the full length version that has 9 exons.
Therefore, the protein size is different; the full length Vimentin version has a protein size of ~57 kDa and the truncated version of ~47 kDa.
We designed an antibody, called Vim3, against the unique C-terminal ending of the Vimentin 3 variant.
Using immune histology, immune fluorescence, Western blot, and qRT-PCR analysis, a Vim3 overexpression was detectable exclusively in oncocytoma, making the detection of Vim3 a potential specific marker for benign kidney tumors.
This antibody is the first to clearly differentiate benign oncocytoma and the mimicking eosinophilic variants of the RCCs.
This differentiation between malignant and benign RCCs is essential for operative planning, follow-up therapy, and patients’ survival.
In the future the usage of Vimentin antibodies in routine pathology has to be applied with care.
Consideration must be given to Vimentin specific binding epitopes otherwise a misdiagnosis of the patients’ tumor samples may result.
American Psychological Association (APA)
von Brandenstein, Melanie& Puetz, Katharina& Schlosser, Monika& Löser, Heike& Kallinowski, Joachim P.& Gödde, Daniel…[et al.]. 2015. Vimentin 3, the New Hope, Differentiating RCC versus Oncocytoma. Disease Markers،Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1060922
Modern Language Association (MLA)
von Brandenstein, Melanie…[et al.]. Vimentin 3, the New Hope, Differentiating RCC versus Oncocytoma. Disease Markers No. 2015 (2015), pp.1-8.
https://search.emarefa.net/detail/BIM-1060922
American Medical Association (AMA)
von Brandenstein, Melanie& Puetz, Katharina& Schlosser, Monika& Löser, Heike& Kallinowski, Joachim P.& Gödde, Daniel…[et al.]. Vimentin 3, the New Hope, Differentiating RCC versus Oncocytoma. Disease Markers. 2015. Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1060922
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1060922